Clinical Trial

Exploring Nasal Drop Therapy With Small Extracellular Vesicles for ALS

Study acronym: de-ALS
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated October 31, 2024 (before its estimated May 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
This is a multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial. The goal of this clinical trial is to evaluate the safety and preliminary efficacy of nasal drop exosomes derived from human umbilical cord blood mesenchymal stem cells (hUC-MSC-sEV-001) in amyotrophic lateral sclerosis.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-13.
Trial Details
NCT Number NCT06598202
Lead Sponsor Xuanwu Hospital, Beijing
Collaborators: Shengqi Medical Technology (Guangzhou) Co., Ltd., Viyun (Xiamen) Biomedical Research Institute Co., Ltd.
Conditions Amyotrophic Lateral Sclerosis
Enrollment 38 participants
Start Date 2024-12-01
Primary Completion 2026-05-30 (estimated)
Study Completion 2026-05-30 (estimated)
Updated on ClinicalTrials.gov 2024-10-31